Variable | Meta-model coefficient | ||||||
---|---|---|---|---|---|---|---|
No imaging QALY | No imaging cost | Incremental QALY CMR, SPECT, CCTAa | Incremental cost CMR, SPECTa | Incremental cost CCTAb | Incremental QALY immediate ICAa | Incremental cost immediate ICAa | |
Intercept | 32.5468 | − 1124.0687 | − 0.0108 | − 930.0 | − 1257.9 | 0.0246 | − 832.2 |
Age in years | − 0.2343 | − 239.1547 | − 0.0002 | 12.8481 | 13.0193 | − 0.0001 | 14.6191 |
Probability of patient having CAD | − 4.0808 | 50,086.6 | 0.1366 | 4335.6 | 3826.9 | n/a | 1643.7 |
Sensitivity of CMR | n/a | n/a | 0.0484 | 1749.6 | n/a | n/a | n/a |
Specificity of CMR | n/a | n/a | 0.0055 | − 2649.1 | n/a | n/a | n/a |
Sensitivity of CCTA | n/a | n/a | n/a | n/a | 1797.7 | n/a | n/a |
Specificity of CCTA | n/a | n/a | n/a | n/a | − 2655.3 | n/a | n/a |
Probability patient with false negative result returns to get coronary angiography within 1 year | 0.0958 | 4034.8 | − 0.0963 | − 3562.4 | − 3595.5 | − 0.1082 | − 4014.4 |
Annual rate of having a new MACE event for patients without CAD | − 75.8 | 287,992.6 | n/a | n/a | n/a | 0.0768 | n/a |
Post-1st year rate of having a MACE event for patients with CAD who received revascularization procedure | − 13.8625 | 29,804.1 | 0.2165 | 16,366.8 | 16,579.2 | 0.2434 | 18,378.7 |
Hazard rate ratio for patients who received medical therapy and revascularization procedure (natural log) | 0.2203 | 528.3 | − 0.1499 | − 577.3 | − 587.7 | − 0.1685 | − 645.2 |
Probability of dying during PCI | n/a | n/a | − 0.2742 | n/a | n/a | − 0.3074 | n/a |
Probability of dying during CABG | n/a | n/a | − 0.1148 | n/a | n/a | − 0.1263 | n/a |
Cost of CMR (or SPECT) | n/a | n/a | n/a | 0.9987 | n/a | n/a | n/a |
Cost of CCTA | n/a | n/a | n/a | n/a | 1.000 | n/a | n/a |
Cost of FFR-CT (added to CCTA for some patients) | n/a | n/a | n/a | n/a | 0.4068 | n/a | n/a |
Cost of immediate coronary angiography with FFR | n/a | n/a | n/a | 0.0534 | 0.0982 | n/a | 0.2967 |
Cost of immediate coronary angiography without FFR | n/a | n/a | n/a | 0.0775 | 0.1416 | n/a | 0.4279 |
Cost of CABG | n/a | 0.0851 | n/a | 0.0131 | 0.0133 | n/a | 0.0147 |
Cost of PCI | n/a | 0.1901 | n/a | 0.0294 | 0.0300 | n/a | 0.0331 |
Acute (1st-year) cost of non-fatal MACE | n/a | 0.1817 | n/a | − 0.0034 | − 0.0038 | n/a | − 0.0045 |
Acute (1st-year) cost of fatal MACE | n/a | 0.1233 | n/a | − 0.0024 | − 0.0021 | n/a | − 0.0032 |
Utility of coronary heart disease health state | 1.0242 | n/a | − 0.0277 | n/a | n/a | − 0.0312 | n/a |
Annual discount rate for costs and QALYs | − 126.8 | − 82,131.3 | − 0.0108 | 5653.8 | 5623.4 | − 0.4461 | 6349.3 |
Meta model performance | No imaging QALY | No imaging Cost | Incremental QALY CMRb | Incremental cost CMRc | Incremental cost CCTAa | Incremental QALY immediate ICAa | Incremental cost immediate ICAa |
---|---|---|---|---|---|---|---|
External validation r-squared | 0.9757 | 0.9133 | 0.9757 | 0.9982 | 0.9861 | 0.9999 | 0.9858 |
External validation deviation compared to Markov model | 0.046% | − 0.025% | − 0.048% to 0.064% | − 0.031% to − 0.018% | 0.007% | − 0.001% | − 0.040% |